TrovaGene Company Profile (NASDAQ:TROV)

About TrovaGene (NASDAQ:TROV)

TrovaGene logoTrovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic & Testing Substances
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TROV
  • CUSIP: N/A
  • Web: www.trovagene.com
Capitalization:
  • Market Cap: $30.56 million
  • Outstanding Shares: 37,269,000
Average Prices:
  • 50 Day Moving Avg: $0.99
  • 200 Day Moving Avg: $1.18
  • 52 Week Range: $0.61 - $5.68
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.12
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $354,234.00
  • Price / Sales: 86.27
  • Book Value: $0.11 per share
  • Price / Book: 7.45
Profitability:
  • EBIDTA: ($29,350,000.00)
  • Net Margins: -10,390.96%
  • Return on Equity: -201.07%
  • Return on Assets: -85.12%
Debt:
  • Current Ratio: 1.16%
  • Quick Ratio: 1.16%
Misc:
  • Average Volume: 918,552 shs.
  • Beta: 0.4
  • Short Ratio: 3.74
 

Frequently Asked Questions for TrovaGene (NASDAQ:TROV)

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

How were TrovaGene's earnings last quarter?

TrovaGene, Inc. (NASDAQ:TROV) announced its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.07. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.34 million. TrovaGene had a negative net margin of 10,390.96% and a negative return on equity of 201.07%. View TrovaGene's Earnings History.

When will TrovaGene make its next earnings announcement?

TrovaGene is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for TrovaGene.

Where is TrovaGene's stock going? Where will TrovaGene's stock price be in 2017?

3 analysts have issued 1-year price objectives for TrovaGene's stock. Their forecasts range from $1.80 to $8.00. On average, they expect TrovaGene's stock price to reach $4.60 in the next twelve months. View Analyst Ratings for TrovaGene.

What are analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:

  • 1. Maxim Group analysts commented, "The in-licensing of PCM-075 (Polo-like Kinase 1 Inhibitor, PLK1) from Nerviano Medical Sciences marked a new chapter for Trovagene as a company in precision cancer therapeutics, targeting acute myeloid leukemia (AML). We spent an evening with Trovagene Management to discuss the program in AML, the clinical path forward and how the company will leverage its knowledge- base in precision cancer monitoring (PCM) to develop PCM-075. There are multiple factors that we see as de-risking and in our view position Tovagene for success in AML. 1. The clinical path forward for a PLK inhibitor in AML has been paved by Boehringer Ingelheim’s (BI) Volasertib. A P1/2 (N=50) dose-ranging and efficacy study is expected to initiate in 2017 (data in 2018). Pending positive data, a P2/3 registration study (N=600) would likely follow. 2. Safety: Volasertib as a pan-PLK inhibitor with IV-only administration and a long half-life induced patient deaths (infections). PCM-075 only targets PLK1 (critical for cancer cell survival), has a 5X shorter half life and is oral. As such PCM-075 may be a safer, more efficacious option. 3. Precision Cancer Monitoring, PCM: Trovagene has the advantage of leveraging its existing AML cancer mutation (NPMI) test that can determine the therapeutic response to PCM-075. The company will also use the PCM platform to develop an AML multi-gene panel. Conclusion. Trovagene is now a therapeutics company and has a distinct advantage in being able to leverage its precision cancer monitoring platform to track therapeutic responses to its drug, PCM-075." (5/5/2017)
  • 2. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (3/15/2017)
  • 3. Cantor Fitzgerald analysts commented, "The partnership with Boreal Genomics is an important milestone for the company, in our view. Per the long-term supply and distribution agreement, 1) TROV commits upfront and milestone payments totaling $1M, 2) TROV has global distribution rights in blood and exclusively in urine for least ten years, and 3) TROV and Boreal will form a joint effort to bring the assay kits and systems through the necessary regulatory pathways for approval. Importantly, TROV continues to target the analytical validation of its initial panel by the end of 2016 and plans to launch a series of cancer-specific multigene ctDNA urine and blood panels, in partnership with Boreal, in 2017. For more details on TROV’s commercialization strategy, please see our September 30, 2016 note. The OnTarget platform separates target mutations from the wild-type. In a one-hour process, the sample is injected into a gel matrix containing short oligo probes that are complementary to the target mutations. The temperature is increased to the melting temperature of the target-probe duplex and target mutations are separated by repeated hybridization in an alternating electric field. Target alleles are collected in the extraction chamber, while the wild-type is removed with more than 1M fold enrichment (and as high as 10M fold)." (11/30/2016)

Who are some of TrovaGene's key competitors?

Who are TrovaGene's key executives?

TrovaGene's management team includes the folowing people:

  • Thomas H. Adams Jr. Ph.D., Chairman of the Board
  • William J. Welch, Chief Executive Officer, Director
  • Paul R. Billings M.D., Ph.D., Independent Director
  • John P. Brancaccio CPA, Independent Director
  • Gary S. Jacob Ph.D., Independent Director
  • Rodney S. Markin M.D., Ph.D., Independent Director
  • Stanley N. Tennant, Independent Director

Who owns TrovaGene stock?

TrovaGene's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (5.70%), CVI INVESTMENTS, INC. (5.70%), Vanguard Group Inc. (1.55%), Goldman Sachs Group Inc. (0.75%), D.A. Davidson & CO. (0.58%) and Susquehanna International Group LLP (0.37%). Company insiders that own TrovaGene stock include Mark Erlander, Stanley Tennant and William J Welch. View Institutional Ownership Trends for TrovaGene.

Who sold TrovaGene stock? Who is selling TrovaGene stock?

TrovaGene's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., D.A. Davidson & CO. and Prospera Financial Services Inc. View Insider Buying and Selling for TrovaGene.

Who bought TrovaGene stock? Who is buying TrovaGene stock?

TrovaGene's stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Susquehanna International Group LLP and LMR Partners LLP. Company insiders that have bought TrovaGene stock in the last two years include Mark Erlander, Stanley Tennant and William J Welch. View Insider Buying and Selling for TrovaGene.

How do I buy TrovaGene stock?

Shares of TrovaGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TrovaGene's stock price today?

One share of TrovaGene stock can currently be purchased for approximately $0.82.


MarketBeat Community Rating for TrovaGene (NASDAQ TROV)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TrovaGene (NASDAQ:TROV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $4.60 (460.98% upside)

Analysts' Ratings History for TrovaGene (NASDAQ:TROV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Maxim GroupSet Price TargetBuy$4.00HighView Rating Details
8/8/2017Cantor FitzgeraldReiterated RatingOverweightHighView Rating Details
3/16/2017Piper Jaffray CompaniesDowngradeNeutral -> UnderweightHighView Rating Details
3/10/2017S&P Equity ResearchBoost Price Target$1.55 -> $1.80N/AView Rating Details
5/12/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
4/28/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Avondale PartnersReiterated RatingMarket Perform$6.00N/AView Rating Details
3/11/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
2/22/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
(Data available from 8/21/2015 forward)

Earnings

Earnings History for TrovaGene (NASDAQ:TROV)
Earnings by Quarter for TrovaGene (NASDAQ:TROV)
Earnings History by Quarter for TrovaGene (NASDAQ TROV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.14)N/AView Earnings Details
5/10/2016Q116($0.29)($0.36)$0.34 million$0.12 millionViewListenView Earnings Details
3/10/2016Q415($0.25)($0.26)$0.14 million$0.08 millionViewListenView Earnings Details
8/10/2015Q215($0.24)($0.41)$0.05 millionViewListenView Earnings Details
5/5/2015($0.23)($0.24)$0.08 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q414($0.26)($0.25)$0.06 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.25)($0.28)$0.05 million$0.06 millionViewN/AView Earnings Details
8/7/2014($0.24)($0.18)$0.05 million$0.06 millionViewN/AView Earnings Details
5/12/2014($0.23)($0.17)$0.05 million$0.11 millionViewN/AView Earnings Details
3/17/2014Q413($0.19)($0.05)$0.15 million$0.05 millionViewN/AView Earnings Details
11/14/2013Q313($0.22)($0.25)ViewN/AView Earnings Details
8/14/2013Q213($0.15)($0.34)ViewN/AView Earnings Details
5/14/2013Q113($0.09)($0.07)$0.03 million$0.12 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TrovaGene (NASDAQ:TROV)
Current Year EPS Consensus Estimate: $-0.86 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS

Dividends

Dividend History for TrovaGene (NASDAQ:TROV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TrovaGene (NASDAQ:TROV)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 15.14%
Insider Trades by Quarter for TrovaGene (NASDAQ:TROV)
Institutional Ownership by Quarter for TrovaGene (NASDAQ:TROV)
Insider Trades by Quarter for TrovaGene (NASDAQ:TROV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Stanley TennantDirectorBuy10,000$2.10$21,000.00View SEC Filing  
12/16/2016Stanley TennantDirectorBuy14,966$2.00$29,932.00View SEC Filing  
12/16/2016William J WelchCEOBuy4,750$2.09$9,927.50View SEC Filing  
12/14/2016Mark ErlanderInsiderBuy5,000$2.08$10,400.00View SEC Filing  
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TrovaGene (NASDAQ:TROV)
Latest Headlines for TrovaGene (NASDAQ:TROV)
Source:
DateHeadline
streetinsider.com logoTrovagene (TROV) Says Its PLK1 Inhibitor PCM-075 Significantly Enhances Efficacy of FLT3 inhibitor in Combination Therapy
www.streetinsider.com - August 17 at 8:34 AM
americanbankingnews.com logoMaxim Group Analysts Give TrovaGene, Inc. (TROV) a $4.00 Price Target
www.americanbankingnews.com - August 16 at 8:26 PM
finance.yahoo.com logoTrovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy
finance.yahoo.com - August 16 at 8:23 AM
americanbankingnews.com logoTrovaGene, Inc. (NASDAQ:TROV) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - August 10 at 5:16 PM
americanbankingnews.com logoTrovaGene, Inc. (NASDAQ:TROV) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - August 10 at 12:46 PM
americanbankingnews.com logoCantor Fitzgerald Weighs in on TrovaGene, Inc.'s FY2017 Earnings (TROV)
www.americanbankingnews.com - August 10 at 9:32 AM
prnewswire.com logoTrovagene Announces Second Quarter 2017 Company Highlights and Financial Results - PR Newswire (press release)
www.prnewswire.com - August 10 at 8:57 AM
finance.yahoo.com logoTrovagene Announces Second Quarter 2017 Company Highlights and Financial Results
finance.yahoo.com - August 10 at 8:57 AM
americanbankingnews.com logoComparing Lantheus Holdings (LNTH) & TrovaGene (TROV)
www.americanbankingnews.com - August 5 at 10:24 AM
americanbankingnews.com logoContrasting Biocept (BIOC) and TrovaGene (TROV)
www.americanbankingnews.com - July 30 at 8:28 AM
prnewswire.com logoTrovagene, Antonius Schuh and Stephen Zaniboni Resolve ... - PR Newswire (press release)
www.prnewswire.com - July 29 at 8:01 AM
finance.yahoo.com logoTrovagene, Antonius Schuh and Stephen Zaniboni Resolve Employment Dispute
finance.yahoo.com - July 29 at 8:01 AM
americanbankingnews.com logoHead-To-Head Comparison: TrovaGene (NASDAQ:TROV) vs. Natera (NTRA)
www.americanbankingnews.com - July 27 at 8:10 PM
prnewswire.com logoTrovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia - PR Newswire (press release)
www.prnewswire.com - July 27 at 8:35 AM
prnewswire.com logoTrovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like ... - PR Newswire (press release)
www.prnewswire.com - July 27 at 8:35 AM
finance.yahoo.com logoTrovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia
finance.yahoo.com - July 27 at 8:35 AM
streetinsider.com logoTrovagene (TROV) Reports Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, a Polo-like Kinase 1 (PLK1) Inhibitor
www.streetinsider.com - July 26 at 9:05 AM
finance.yahoo.com logoTrovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor
finance.yahoo.com - July 26 at 9:05 AM
finance.yahoo.com logoTrovagene, Inc. Provides Company Overview and Discusses Clinical Development Plans for PCM-075 in New SNNLive Video Interview with StockNewsNow.com
finance.yahoo.com - July 26 at 9:05 AM
americanbankingnews.com logoTrovaGene, Inc. (NASDAQ:TROV) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:48 AM
reuters.com logoBRIEF-CVI Investments Inc reports 5.7 percent passive stake in Trovagene as of July 13 - SEC filing
www.reuters.com - July 25 at 7:48 AM
streetinsider.com logoForm SC 13G Trovagene, Inc. Filed by: SABBY MANAGEMENT, LLC - StreetInsider.com
www.streetinsider.com - July 18 at 9:13 AM
reuters.com logoBRIEF-Trovagene announces $7.1 million registered direct offering
www.reuters.com - July 15 at 2:17 AM
finance.yahoo.com logoFeatured Company News – Trovagene Sells Its Proprietary Urine Collection And Nucleic Acid Preservation Device Nextcollect(TM) To Novogene
finance.yahoo.com - July 14 at 9:22 AM
finance.yahoo.com logoTrovagene Announces $7.1 Million Registered Direct Offering
finance.yahoo.com - July 14 at 9:22 AM
americanbankingnews.com logoAnalyzing NanoString Technologies (NSTG) and TrovaGene (TROV)
www.americanbankingnews.com - July 12 at 8:48 PM
streetinsider.com logoForm 8-K Trovagene, Inc. For: Jul 12 - StreetInsider.com
www.streetinsider.com - July 12 at 8:22 AM
prnewswire.com logoTrovagene, Inc. Regains Compliance with NASDAQ Listing Requirements - PR Newswire (press release)
www.prnewswire.com - July 12 at 8:22 AM
finance.yahoo.com logoTrovagene Announces Agreement with Novogene for NextCollect™ in China
finance.yahoo.com - July 12 at 8:22 AM
finance.yahoo.com logoTrovagene, Inc. Regains Compliance with NASDAQ Listing Requirements
finance.yahoo.com - July 11 at 8:38 AM
americanbankingnews.com logoTrovaGene (NASDAQ:TROV) vs. Biocept (BIOC) Head-To-Head Survey
www.americanbankingnews.com - July 9 at 8:22 AM
prnewswire.com logoTrovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075 - PR Newswire (press release)
www.prnewswire.com - July 8 at 2:54 PM
finance.yahoo.com logoTrovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075
finance.yahoo.com - July 6 at 2:23 PM
streetinsider.com logoForm 8-K Trovagene, Inc. For: Jun 29 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - June 29 at 3:23 PM
finance.yahoo.com logoTrovagene Announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial
finance.yahoo.com - June 29 at 3:23 PM
americanbankingnews.com logoTrovaGene (TROV) & Quotient Limited (QTNT) Financial Comparison
www.americanbankingnews.com - June 29 at 7:50 AM
prnewswire.com logoTrovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM ... - PR Newswire (press release)
www.prnewswire.com - June 29 at 7:32 AM
seekingalpha.com logoTrovaGene, Inc. (TROV)
seekingalpha.com - June 29 at 7:32 AM
americanbankingnews.com logoTrovaGene, Inc. (TROV) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - June 28 at 2:32 PM
streetinsider.com logoTrovagene (TROV) Expands Key Claims for NPM1 Patent Portfolio for AML
www.streetinsider.com - June 28 at 1:32 AM
streetinsider.com logoForm 8-K Trovagene, Inc. For: Jun 27 - StreetInsider.com
www.streetinsider.com - June 27 at 9:20 AM
seekingalpha.com logoTrovagene receives default notice from lender; shares down 8% - Seeking Alpha
seekingalpha.com - June 27 at 9:20 AM
finance.yahoo.com logoTrovagene Announces Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia
finance.yahoo.com - June 27 at 9:20 AM
finance.yahoo.com logoTrovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia
finance.yahoo.com - June 27 at 9:19 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Oracle, Steelcase, Kadmon ... - Nasdaq
www.nasdaq.com - June 22 at 7:20 PM
streetinsider.com logoForm 8-K Trovagene, Inc. For: Jun 22 - StreetInsider.com
www.streetinsider.com - June 22 at 7:20 PM
streetinsider.com logoTrovagene (TROV) Reports Agreement with Global Biopharmaceutical Company to Utilize Trovera ctDNA Tests & Services in Cancer Clinical Trials
www.streetinsider.com - June 22 at 2:18 PM
finance.yahoo.com logoTrovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera® ctDNA Tests and Services in Cancer Clinical Trials
finance.yahoo.com - June 22 at 2:18 PM
americanbankingnews.com logoTrovaGene's (TROV) "Buy" Rating Reiterated at Maxim Group
www.americanbankingnews.com - June 13 at 10:58 AM
prnewswire.com logoTrovagene Enters Into Agreement with AstraZeneca to Utilize ... - PR Newswire (press release)
www.prnewswire.com - June 13 at 9:25 AM

Social

Chart

TrovaGene (TROV) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by MarketBeat.com Staff